| Prev Close | 1.16 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.71 / 1.73 |
| Avg Volume | 393.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 56.42M |
| Market Cap | 67.71M |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY
- Presentation includes details of 2017 operating plan and five-year Company vision -
BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference
Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C
BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML
BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China
JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations -
BioLineRx To Report Second Quarter Results On August 11, 2016
Management to hold conference call at 10:00 a.m. EDT
BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration
Novel drug candidate modulates immune system to reduce liver fibrosis in non-alcoholic steatohepatitis
BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
- Study expected to commence during Q3 2016 -
BioLineRx To Report First Quarter 2016 Results On May 17, 2016
Management to hold a conference call at 10:00 a.m. EDT
7 Stocks Under $10 to Trade for Big Profits
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016
- Results identify specific targets in the apoptotic pathway -
7 Stocks Under $10 Making Big Moves
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML
Data identify a potential biomarker for future selection of BL-8040-responsive AML patients
BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
Partial results expected by end of 2016
BioLineRx To Report Annual 2015 Results On March 10, 2016
Management to hold a conference call at 10:00 a.m. EST
BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment
BL-7010 receives designation as Class IIb medical device
BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
BioLineRx management to hold conference call this morning at 10:00 am EST to further discuss this immunotherapy collaboration